Use of dopaminergic agents in the treatment-resistant depression

Simple item page
dc.creatorRodríguez-Bores, Lorenaes_ES
dc.creatorFlores-Ramos, Mónicaes_ES
dc.creatorCampuzano, Rafaeles_ES
dc.date2015
dc.date.accessioned2025-11-20T18:52:34Z
dc.date.accessioned2026-03-27T15:33:55Z
dc.date.available2025-11-20T18:52:34Z
dc.date.issued2015
dc.date.published2015
dc.descriptionBackground: The term Treatment- Resistant Depression is frequently used to describe patients that show poor response to conventional antidepressant therapy. Therefore a search for better and more efficacious treatment options is needed. The dopaminergic hypothesis for depression has been an attractive topic according to the growing evidence from basic research and clinical trials that have suggested the important role of this neurotransmitter in the pathophysiology of depression. Currently, the dopaminergic drugs used in clinical practice are employed mainly for neuropsychiatric conditions and some of them specifically pramipexole and ropirinole have exhibited an antidepressant action that had led to the postulate that these may be considered as potential agents with antidepressive effects. Objective: Our aim was to explore current data from preclinical and clinical trials that place pramipexole and ropirinole as options for augmentation strategies. Method: We performed a literature review about the use of dopaminergic agents to provide an overview about its efficacy and safety in the treatment of treatment-resistant depression. Conclusion: Reviewing briefly the hypothetical role of dopamine mechanisms in depression, the findings from basic research, nonclinical studies and clinical trials, we certainly can say that dopaminergic drugs had brought a broad opportunity with novel benefits and risks to the mood disorders treatment, although further research and more randomized controlled trials in larger samples are needed to prove their efficacy and safety.es_ES
dc.formatPDFes_ES
dc.identifier.doi10.2174/2211556004666151008214105
dc.identifier.eissn2211-5579
dc.identifier.issn2211-5560
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.placeEmiratos Árabes Unidos
dc.identifier.urihttp://doi.org/10.2174/2211556004666151008214105
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/8511
dc.language.isoenges_ES
dc.publisherBentham Sciencees_ES
dc.relation4(2):70-75
dc.relation.jnabreviadoCURR PSYCHOPHARMACOL
dc.relation.journalCurrent Psychopharmacology
dc.rightsAcceso Cerradoes_ES
dc.subject.kwDepression
dc.subject.kwDopaminergic agents
dc.subject.kwTreatment-resistant depression
dc.subject.kwPrmipexole
dc.titleUse of dopaminergic agents in the treatment-resistant depressiones_ES
dc.typeArtículoes_ES

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Artículos de revista